摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(4-methylbenzyl)-2-phenyl-1H-benzo[d]imidazole

中文名称
——
中文别名
——
英文名称
1-(4-methylbenzyl)-2-phenyl-1H-benzo[d]imidazole
英文别名
1-(4-methylbenzyl)-2-phenyl-1H-benzimidazole;1-(4-methylbenzyl)-2-phenylbenzo[d]imidazole;1-[(4-Methylphenyl)methyl]-2-phenyl-1H-1,3-benzodiazole;1-[(4-methylphenyl)methyl]-2-phenylbenzimidazole
1-(4-methylbenzyl)-2-phenyl-1H-benzo[d]imidazole化学式
CAS
——
化学式
C21H18N2
mdl
MFCD02858834
分子量
298.387
InChiKey
GGSONIMAPMHFEF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.1
  • 重原子数:
    23
  • 可旋转键数:
    3
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.1
  • 拓扑面积:
    17.8
  • 氢给体数:
    0
  • 氢受体数:
    1

反应信息

  • 作为反应物:
    描述:
    1-(4-methylbenzyl)-2-phenyl-1H-benzo[d]imidazole 、 zinc(II) chloride 以 乙醇 为溶剂, 反应 5.0h, 以85%的产率得到dichlorobis(1-(4-methylbenzyl)-2-phenyl-1H-benzimidazole-κN3)zinc(II)
    参考文献:
    名称:
    Synthesis and evaluation of anticancer properties of novel benzimidazole ligand and their cobalt(II) and zinc(II) complexes against cancer cell lines A-2780 and DU-145
    摘要:
    Eighteen new cobalt(II) or zinc(II) complexes of benzimidazole bearing 1-benzyl and 2-phenyl moieties were synthesized from the reaction of appropriate benzimidazole ligands and CoCl2 or ZnCl2. Their structural characterizations were done by IR, NMR (H-1, C-13) and UV-VIS spectrometers. Cytotoxic activities of eighteen new complexes and three benzimidazole ligands were determined using A-2780 (human ovarian) and DU-145 (human prostate) cell lines. Antitumor properties of all compounds were determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Cell viability assay for the tested benzimidazole derivatives was performed and the LogIC(50) values of the compounds were calculated after a 24-hour treatment. All tested benzimidazole derivatives showed higher or comparable antitumor activity against A-2780 cell lines compared to the standard drug docetaxel with a LogIC(50) value of -0.81 mu M (p < 0.05). Eight of the examined compounds (1, 3, 5, 6, 7, 9, 10 and 13) showed high cytotoxic activity against A-2780 compared to the standard drug docetaxel. While the LogIC(50) of the docetaxel was -0.81 mu M for A-2780 cells at 24 h, the IC50 values of compounds 1, 3, 5, 6, 7, 9, 10 and 13 were - 0.97, -1.30, - 0.22, 0.13, - 0.16, - 0.73 and - 0.53 mu M, respectively. Three of the compounds 1, 18 and V showed high cytotoxic activity against DU-145 compared to docetaxel (p < 0.05). While the LogIC(50) of the docetaxel was -1.13 mu M for DU-145 cells at 24 h, the LogIC(50) values of compounds 1, 18 and V were 0.84, -0.38 and -0.66 mu M, respectively.
    DOI:
    10.1016/j.ica.2019.118977
  • 作为产物:
    描述:
    参考文献:
    名称:
    Development of benzimidazole-based derivatives as antimicrobial agents and their synergistic effect with colistin against gram-negative bacteria
    摘要:
    Gram-negative bacteria pose a distinctive risk worldwide, especially with the evolution of major resistance to carbapenems, fluoroquinolones and colistin. Therefore, development of new antibacterial agents to target Gram-negative infections is of utmost importance. Using phenotypic screening, we synthesized and tested thirty-one benzimidazole derivatives against E. coli JW55031 (TolC mutant strain). Compound 6c showed potent activity with MlC value of 2 mu g/ml, however, it lacked activity against several Gram-negative microbes with intact efflux systems, including E. coli BW25113 (wild-type strain). Combination of 6c with colistin partially restored its antibacterial activity against wild strains (MlC range, 8-16 mu g/ml against E. coli, K. pneumoniae, A. baumannii, and P. aeruginosa). 6c exhibited no cytotoxicity against two mammalian cell lines. Therefore, compound 6c represents a promising lead for further optimization to overcome Gram-negative resistance alone or in combination therapy. (C) 2019 Elsevier Masson SAS. All rights reserved.
    DOI:
    10.1016/j.ejmech.2019.111850
点击查看最新优质反应信息

文献信息

  • An intramolecular C(sp<sup>3</sup>)–H imination using PhI–<i>m</i>CPBA
    作者:Anima Bose、Saikat Maiti、Sudip Sau、Prasenjit Mal
    DOI:10.1039/c8cc09100e
    日期:——

    Development of sustainable methods for the activation of less reactive undirected C(sp3)–H bonds is challenging but desired in organic synthesis. The present manuscript demonstrates selective activation of acidic C(sp3)–H groups for a dehydrogenative C–H imination reaction by 4H elimination using PhI (10 mol%)–mCPBA as an organocatalyst.

    开发可持续方法来活化较不活泼的无向C(sp³)–H键在有机合成中具有挑战性但是受欢迎。本手稿展示了使用PhI (10 mol%)–mCPBA作为有机催化剂进行脱氢C–H亚胺化反应,实现对酸性C(sp³)–H基团的选择性活化。
  • One-pot strategy of copper-catalyzed synthesis of 1,2-disubstituted benzimidazoles
    作者:Caixia Xie、Xushuang Han、Jian Gong、Danyang Li、Chen Ma
    DOI:10.1039/c7ob00945c
    日期:——
    A simple, one-pot and copper-catalyzed coupling reaction for the construction of 1,2-disubstituted benzimidazole derivatives is described. Low-cost copper salt and weak base K3PO4 were utlized in this reaction. A variety of 1,2-disubstituted benzimidazoles were obtained in moderate to excellent yields.
    描述了一种简单的,一锅法和铜催化的偶联反应,用于构建1,2-二取代的苯并咪唑衍生物。在该反应中使用了廉价的铜盐和弱碱K3PO4。以中等至优异的产率获得了各种1,2-二取代的苯并咪唑。
  • Intramolecular C(sp<sup>3</sup> )-H Imination towards Benzimidazoles Using Tetrabutylammonium Iodide and <i>t</i> BuOOH
    作者:Anima Bose、Sudip Sau、Prasenjit Mal
    DOI:10.1002/ejoc.201900732
    日期:2019.7.7
    For the synthesis of benzimidazoles, an intramolecular C(sp3)–H imination is described by in situ formation of catalytic hypoiodite(I) or iodite(III) from water soluble inorganic iodide(I) reagent and mild oxidant TBHP.
    对于苯并咪唑的合成,通过从水溶性无机碘化物(I)试剂和弱氧化剂TBHP原位形成催化次碘酸盐(I)或碘化物(III)来描述分子内C(sp 3)-H酰亚胺化。
  • Application of Bertagnini's Salts in a Mechanochemical Approach Toward Aza‐Heterocycles and Reductive Aminations via Imine Formation
    作者:Sourav Behera、Shyamal Kanti Bera、Francesco Basoccu、Federico Cuccu、Pietro Caboni、Lidia De Luca、Andrea Porcheddu
    DOI:10.1002/adsc.202301407
    日期:——
    with solid reagents. We have showcased the practicality of Bertagnini's salts, also called aldehyde-bisulfite adducts, which are crystalline, simplifying preparation and storage. These salts are stable substitutes for liquid aldehydes and ketones that have been effectively employed in reductive amination, synthesizing aza-heterocycles and hydrazones within mechanochemistry. The technique's effectiveness
    我们的研究表明,使用固体试剂进行机械化学活化更有效。我们展示了贝尔塔尼尼盐(也称为醛-亚硫酸氢盐加合物)的实用性,它们是结晶,简化了制备和储存。这些盐是液体醛和酮的稳定替代品,可有效用于机械化学中的还原胺化、氮杂杂环和腙的合成。该技术的有效性拓宽了底物范围,简化了纯化,减少了反应时间,并提供了良好的产物收率。此外,亚硫酸氢盐加合物的热稳定性已通过 TGA(热重分析)分析得到证实。
  • Development of benzimidazole-based derivatives as antimicrobial agents and their synergistic effect with colistin against gram-negative bacteria
    作者:Eman M.E. Dokla、Nader S. Abutaleb、Sandra N. Milik、Daoyi Li、Karim El-Baz、Menna-Allah W. Shalaby、Rawan Al-Karaki、Maha Nasr、Christian D. Klein、Khaled A.M. Abouzid、Mohamed N. Seleem
    DOI:10.1016/j.ejmech.2019.111850
    日期:2020.1
    Gram-negative bacteria pose a distinctive risk worldwide, especially with the evolution of major resistance to carbapenems, fluoroquinolones and colistin. Therefore, development of new antibacterial agents to target Gram-negative infections is of utmost importance. Using phenotypic screening, we synthesized and tested thirty-one benzimidazole derivatives against E. coli JW55031 (TolC mutant strain). Compound 6c showed potent activity with MlC value of 2 mu g/ml, however, it lacked activity against several Gram-negative microbes with intact efflux systems, including E. coli BW25113 (wild-type strain). Combination of 6c with colistin partially restored its antibacterial activity against wild strains (MlC range, 8-16 mu g/ml against E. coli, K. pneumoniae, A. baumannii, and P. aeruginosa). 6c exhibited no cytotoxicity against two mammalian cell lines. Therefore, compound 6c represents a promising lead for further optimization to overcome Gram-negative resistance alone or in combination therapy. (C) 2019 Elsevier Masson SAS. All rights reserved.
查看更多